Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2015

View Archived Issues

Gene delivery therapy shows promising effects on experimental autoimmune myocarditis

AstraZeneca reviews recent pipeline activities of second quarter 2015

Novel potent and selective EP4 receptor antagonist for pain-management

Orkambi benefits patients with cystic fibrosis in phase III studies; product launch underway

The J. David Gladstone Institutes divulge autophagy inducers

Lilly designs FFAR1 agonists

Mitsubishi Tanabe Pharma presents milestones of first quarter of fiscal 2015

CSL completes acquisition of Novartis influenza vaccine business

First 3D printed drug product approved by FDA

FDA grants orphan drug designation to veltuzumab for ITP

The European Comission grants orphan drug designation to Soligenix's SGX-301

Exalenz Bioscience's BreathID to be tested in GR-MD-02 trial

Teva to buy controlling interest in analytics company Immuneering

Euclises Pharmaceuticals patents COX-2 inhibitors/NO-releasing prodrugs

Columbia University in the City of New York discloses SLC7A11 inhibitors

3-V Biosciences describes fatty acid synthase inhibitors

Merck Patent synthesizes IRAK inhibitors

Celgene exercises option to license GI-6207

Progenics forms agreement with Johns Hopkins University for prostate cancer imaging agent

CureVac and Gates Foundation to collaborate on RSV vaccine development

Minerva Biotechnologies licenses iPSC IP from iPS Academia Japan

MedImmune and Mirati to conduct trial combining durvalumab and mocetinostat

Anavex Life Sciences discloses preliminary phase IIa results for Anavex 2-73

Pharmaxis and Synairgen form collaboration to target LOXL2 for IPF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...